NATCO Pharma Beheer
Beheer criteriumcontroles 1/4
De CEO NATCO Pharma is Rajeev Nannapaneni, benoemd in Jun2012, heeft een ambtstermijn van 12.42 jaar. bezit rechtstreeks 0.63% van de aandelen van het bedrijf, ter waarde ₹ 1.61B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.8 jaar en 2.3 jaar.
Belangrijke informatie
Rajeev Nannapaneni
Algemeen directeur
₹98.7m
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 12.4yrs |
| Eigendom CEO | 0.6% |
| Management gemiddelde ambtstermijn | 7.8yrs |
| Gemiddelde ambtstermijn bestuur | 2.3yrs |
Recente managementupdates
Recent updates
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13
NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02CEO
Rajeev Nannapaneni (47 yo)
12.4yrs
Tenure
₹98,670,000
Compensatie
Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Chairman | 43.2yrs | ₹100.77m | 25.1% ₹ 64.2b | |
| CEO & Vice Chairman | 12.4yrs | ₹98.67m | 0.63% ₹ 1.6b | |
| Chief Financial Officer | 8.8yrs | ₹13.36m | geen gegevens | |
| President of Technical Affairs & Whole Time Director | no data | ₹33.69m | 0.030% ₹ 77.3m | |
| Company Secretary & Compliance Officer | 2.6yrs | ₹2.61m | geen gegevens | |
| Executive VP of Corporate Engineering Services & Whole Time Director | no data | ₹20.16m | 0.023% ₹ 58.7m | |
| Executive VP of Technical Operations & Director | 7.8yrs | ₹32.12m | 0.013% ₹ 33.2m | |
| VP & Head of Operations | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Corporate Affairs | no data | geen gegevens | geen gegevens | |
| Vice President of Marketing & Sales - Domestic | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of HR & Organisational Development | no data | geen gegevens | 0.0062% ₹ 15.8m | |
| Executive Vice President of R&D | 30.6yrs | geen gegevens | 0.025% ₹ 62.9m |
7.8yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NATCOPHARM is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Chairman | 43.2yrs | ₹100.77m | 25.1% ₹ 64.2b | |
| CEO & Vice Chairman | 19yrs | ₹98.67m | 0.63% ₹ 1.6b | |
| President of Technical Affairs & Whole Time Director | 9.8yrs | ₹33.69m | 0.030% ₹ 77.3m | |
| Executive VP of Corporate Engineering Services & Whole Time Director | 10yrs | ₹20.16m | 0.023% ₹ 58.7m | |
| Executive VP of Technical Operations & Director | 2.3yrs | ₹32.12m | 0.013% ₹ 33.2m | |
| Independent Director | 9.8yrs | ₹330.00k | geen gegevens | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NATCOPHARM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.